[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1120416A1 - Multivalent pneumococcal polysaccharide-protein conjugate composition - Google Patents

Multivalent pneumococcal polysaccharide-protein conjugate composition

Info

Publication number
HK1120416A1
HK1120416A1 HK08112248.7A HK08112248A HK1120416A1 HK 1120416 A1 HK1120416 A1 HK 1120416A1 HK 08112248 A HK08112248 A HK 08112248A HK 1120416 A1 HK1120416 A1 HK 1120416A1
Authority
HK
Hong Kong
Prior art keywords
protein conjugate
conjugate composition
pneumococcal polysaccharide
multivalent pneumococcal
multivalent
Prior art date
Application number
HK08112248.7A
Other languages
English (en)
Inventor
William P Hausdorff
George Rainer Siber
Peter R Paradiso
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36709976&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1120416(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of HK1120416A1 publication Critical patent/HK1120416A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
HK08112248.7A 2005-04-08 2008-11-07 Multivalent pneumococcal polysaccharide-protein conjugate composition HK1120416A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66960505P 2005-04-08 2005-04-08
PCT/US2006/012354 WO2006110381A1 (en) 2005-04-08 2006-03-31 Multivalent pneumococcal polysaccharide-protein conjugate composition

Publications (1)

Publication Number Publication Date
HK1120416A1 true HK1120416A1 (en) 2009-04-03

Family

ID=36709976

Family Applications (3)

Application Number Title Priority Date Filing Date
HK08112248.7A HK1120416A1 (en) 2005-04-08 2008-11-07 Multivalent pneumococcal polysaccharide-protein conjugate composition
HK16101175.7A HK1213184A1 (zh) 2005-04-08 2016-02-02 多價肺炎球菌多糖-蛋白質綴合物組合物
HK19100324.6A HK1257962A1 (zh) 2005-04-08 2019-01-09 多價肺炎球菌多糖-蛋白質綴合物組合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK16101175.7A HK1213184A1 (zh) 2005-04-08 2016-02-02 多價肺炎球菌多糖-蛋白質綴合物組合物
HK19100324.6A HK1257962A1 (zh) 2005-04-08 2019-01-09 多價肺炎球菌多糖-蛋白質綴合物組合物

Country Status (29)

Country Link
US (9) US20060228380A1 (es)
EP (9) EP2425856A1 (es)
JP (3) JP4472770B2 (es)
KR (11) KR20150061019A (es)
CN (6) CN113198012B (es)
AR (2) AR053354A1 (es)
AT (1) ATE548051T1 (es)
AU (1) AU2006235013B2 (es)
BR (1) BRPI0607025B8 (es)
CA (4) CA3165042A1 (es)
CL (2) CL2016000566A1 (es)
CY (1) CY1112777T1 (es)
DK (1) DK1868645T3 (es)
ES (1) ES2382048T3 (es)
HK (3) HK1120416A1 (es)
HR (1) HRP20120278T1 (es)
IL (5) IL308456A (es)
ME (1) ME01334B (es)
MX (3) MX358148B (es)
MY (1) MY145150A (es)
NZ (1) NZ562406A (es)
PL (1) PL1868645T3 (es)
PT (1) PT1868645E (es)
RS (1) RS52249B (es)
SA (1) SA06270323B1 (es)
SI (1) SI1868645T1 (es)
TW (3) TWI386222B (es)
WO (1) WO2006110381A1 (es)
ZA (1) ZA200709483B (es)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3165042A1 (en) 2005-04-08 2006-10-19 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
KR101351870B1 (ko) * 2005-06-27 2014-02-17 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
JP5579387B2 (ja) 2005-12-22 2014-08-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 肺炎連鎖球菌莢膜多糖類コンジュゲートを含むワクチン
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
AU2013200552B9 (en) * 2006-04-07 2014-07-03 Glaxosmithkline Biologicals S.A. Conjugate vaccines
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2012216628B9 (en) * 2006-04-26 2021-10-21 Wyeth Llc Novel Formulations which Stabilize and Inhibit Precipitation of Immunogenic Compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
ES2614249T3 (es) * 2007-03-23 2017-05-30 Wyeth Llc Procedimiento abreviada de purificación para la producción de polisacáridos capsulares de Streptococcus pneumoniae
WO2008129559A2 (en) 2007-04-23 2008-10-30 Serum Institute Of India Ltd Antigenic polysaccharides and process for their preparation
EP2682127A1 (en) * 2007-05-02 2014-01-08 GlaxoSmithKline Biologicals S.A. Vaccine
EP2687228B1 (en) * 2007-06-26 2017-07-19 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0713880D0 (en) * 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0818453D0 (en) * 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2009106085A1 (en) * 2008-02-28 2009-09-03 Nordic Vaccine A/S Vaccine compositions comprising saccharide antigens
WO2009143413A1 (en) * 2008-05-22 2009-11-26 Children'smedical Center Corporation Synergistic immunogenic fusion protein-polysaccharide conjugate
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
RU2511404C2 (ru) 2008-12-18 2014-04-10 УАЙТ ЭлЭлСи Способ получения раствора, содержащего высокомолекулярные изолированные капсульные полисахариды streptococcus pneumoniae серотипа 19а (варианты)
RU2524436C2 (ru) 2008-12-18 2014-07-27 УАЙТ ЭлЭлСи Способ получения жидкой фракции, содержащей изолированные высокомолекулярные капсульные полисахариды streptococcus pneumoniae, и жидкая фракция, полученная таким способом
RU2555757C2 (ru) 2009-03-24 2015-07-10 Новартис Аг Комбинации менингококкового фактор н-связывающего белка и пневмококковых сахаридных конъюгатов
JP5597245B2 (ja) 2009-03-24 2014-10-01 ノバルティス アーゲー アジュバント添加した髄膜炎菌ｈ因子結合タンパク質
CA2757620C (en) 2009-04-30 2016-04-26 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
CN101785857B (zh) * 2010-03-05 2012-09-26 成都安特金生物技术有限公司 一种新的肺炎球菌结合疫苗及其制备方法
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
WO2011148382A1 (en) 2010-05-28 2011-12-01 Biological E Limited An improved process for the purification of capsular polysaccharides of haemophilus influenza - b, neisseria meningitis such as serotypes a, c, y and w-135, and other similar related capsular polysaccharides produced from both gram negative and gram positive microorganisms using aluminium phosphate with alcohol.
PL3170508T3 (pl) 2010-06-04 2020-04-30 Wyeth Llc Preparaty szczepionek
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
AU2012222883A1 (en) 2011-03-02 2013-10-17 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
KR101315599B1 (ko) * 2011-10-25 2013-10-10 건국대학교 산학협력단 폐렴균점막다당질 유형14 （ｃｐｓ１４）와 호스래디시 퍼옥시다제의 당단백중합체
EP2797624A1 (en) 2011-12-29 2014-11-05 Novartis AG Adjuvanted combinations of meningococcal factor h binding proteins
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
KR102057217B1 (ko) * 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CN104487086B (zh) * 2012-07-07 2019-08-30 巴拉特生物技术国际有限公司 无动物源的不含酒精的疫苗组合物及其制备方法
MX363511B (es) 2012-08-16 2019-03-26 Pfizer Proceso de glucoconjugación y composiciones.
JP6324961B2 (ja) 2012-09-06 2018-05-16 ノバルティス アーゲー 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
RU2606022C2 (ru) 2012-09-07 2017-01-10 Ск Кемикалс Ко., Лтд. Способ получения капсульного полисахарида с пневмококковым серотипом
KR20140075201A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075196A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
US20150320852A1 (en) 2012-12-18 2015-11-12 Glaxosmithkline Biologicals Sa Conjugates for protecting against diphtheria and/or tetanus
ITMI20130142A1 (it) 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
CN104151426A (zh) * 2013-05-14 2014-11-19 北京天成新脉生物技术有限公司 肺炎链球菌十三种荚膜多糖单克隆抗体及其应用
CN103495161B (zh) * 2013-10-08 2019-06-18 江苏康泰生物医学技术有限公司 一种多元肺炎球菌荚膜多糖-蛋白质结合物的混合物及其制备方法
CA3170344C (en) * 2014-01-21 2023-08-29 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN105934251A (zh) 2014-01-21 2016-09-07 辉瑞大药厂 肺炎链球菌荚膜多糖及其缀合物
ES2883571T3 (es) 2014-01-21 2021-12-09 Pfizer Polisacáridos capsulares de Streptococcus pneumoniae y conjugados de los mismos
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
ES2701169T3 (es) 2014-02-14 2019-02-21 Pfizer Conjugados glucoproteicos inmunogénicos
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
HRP20230416T1 (hr) 2015-01-15 2023-07-07 Pfizer Inc. Imunogeni pripravci, namijenjeni upotrebi u cjepivima protiv pneumokoka
SG11201708242YA (en) * 2015-05-04 2017-11-29 Pfizer Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
PL3313436T3 (pl) 2015-06-23 2021-06-14 Biological E Limited Wielowartościowa skoniugowana szczepionka przeciw pneumokokom
RU2721128C2 (ru) 2015-07-21 2020-05-18 Пфайзер Инк. Иммуногенные композиции, содержащие конъюгированные антигены капсульного сахарида, наборы, содержащие эти композиции, и их применения
MY187472A (en) * 2015-09-10 2021-09-23 Inventprise Llc Multivalent vlp conjugates
EP3377098A1 (en) 2015-11-20 2018-09-26 Pfizer Inc Immunogenic compositions for use in pneumococcal vaccines
MX2019001341A (es) 2016-08-05 2019-07-04 Sanofi Pasteur Inc Composicion de conjugado de polisacarido neumococico multivalente-proteina.
AU2017306711B2 (en) * 2016-08-05 2022-08-04 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2018048141A1 (ko) * 2016-09-06 2018-03-15 주식회사 엘지화학 다가 협막 다당류-운반 단백질을 포함하는 조성물 및 이의 용도
MX2019003593A (es) 2016-09-30 2019-06-10 Biological E Ltd Composiciones de vacuna neumococica multivalente que comprenden conjugados de polisacaridos y proteinas.
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
CN110366428B (zh) 2016-12-30 2024-05-17 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
AU2018208844B2 (en) * 2017-01-20 2021-02-25 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2018144439A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for making polysaccharide-protein conjugates
KR102650073B1 (ko) * 2017-01-31 2024-03-20 머크 샤프 앤드 돔 엘엘씨 스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
US11246918B2 (en) 2017-02-03 2022-02-15 Eva Barbara Schadeck Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
AU2018225099B2 (en) 2017-02-24 2024-08-22 Merck Sharp & Dohme Llc Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates
US20200054740A1 (en) * 2017-02-24 2020-02-20 Merck Sharp & Dohme Corp. Pneumococcal conjugate vaccine formulations
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
KR102028693B1 (ko) * 2017-04-27 2019-10-04 주식회사 유바이오로직스 스트렙토코커스 뉴모니아 협막 다당체의 생산방법
KR20240018698A (ko) 2017-06-10 2024-02-13 인벤트프라이즈 인크. 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CA3067587A1 (en) 2017-06-23 2018-12-27 Nosocomial Vaccine Corporation Immunogenic compositions
EP3431168A1 (en) * 2017-07-19 2019-01-23 Bayer Aktiengesellschaft Élimination de médicament non lié après couplage conjugué anticorps-médicament
CN111065388A (zh) * 2017-09-07 2020-04-24 默沙东公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
WO2019050815A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
CN116898959A (zh) 2017-09-07 2023-10-20 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
KR20200051005A (ko) 2017-09-07 2020-05-12 머크 샤프 앤드 돔 코포레이션 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도
EA202091382A1 (ru) 2017-12-06 2021-01-15 Мерк Шарп И Доум Корп. Композиции, содержащие конъюгаты полисахарид streptococcus pneumoniae с белком, и способы их применения
AU2019215212A1 (en) * 2018-02-05 2020-07-23 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
CA3089007A1 (en) 2018-02-05 2019-08-08 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2019178364A2 (en) * 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
TW202011985A (zh) * 2018-04-18 2020-04-01 韓商Ｓｋ生物科學股份有限公司 肺炎鏈球菌的莢膜多醣類以及其免疫原性接合體
CN112074294A (zh) * 2018-04-30 2020-12-11 默沙东公司 从冻干球生产肺炎链球菌荚膜多糖载体蛋白缀合物的方法
CN112041435B (zh) 2018-04-30 2024-05-31 默沙东有限责任公司 提供冻干的突变白喉毒素在二甲基亚砜中的均质溶液的方法
JP7506605B6 (ja) 2018-04-30 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌莢膜多糖類担体タンパク質複合体の製造方法
WO2019220304A1 (en) * 2018-05-14 2019-11-21 Tergene Biotech Pvt. Ltd. 15 valent pneumococcal polysaccharide conjugate vaccine
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
SG11202012905PA (en) 2018-07-04 2021-01-28 Vaxcyte Inc Improvements in immunogenic conjugates
WO2020010000A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
TW202019470A (zh) * 2018-09-12 2020-06-01 美商艾芬尼維克斯公司 多價肺炎球菌疫苗
CN113194987B (zh) * 2018-10-12 2024-11-08 生物E有限公司 多价肺炎球菌多糖-蛋白缀合的疫苗
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
EP3897705A2 (en) 2018-12-19 2021-10-27 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN110302375A (zh) * 2019-06-27 2019-10-08 康希诺生物股份公司 一种糖缀合物及其用途
WO2021021729A1 (en) 2019-07-31 2021-02-04 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
CN112741901B (zh) * 2019-10-31 2024-05-10 北京科兴中维生物技术有限公司 一种含有5型肺炎链球菌荚膜多糖的疫苗及其制备方法
KR20220092572A (ko) 2019-11-01 2022-07-01 화이자 인코포레이티드 에스케리키아 콜라이 조성물 및 그 방법
WO2021146681A1 (en) * 2020-01-17 2021-07-22 Inventprise, Llc Multivalent streptococcus vaccines
IL295713A (en) * 2020-02-21 2022-10-01 Pfizer Isolation of saccharides
IL295632A (en) 2020-02-23 2022-10-01 Pfizer Escherichia coli preparations and their methods
EP4192499A4 (en) 2020-08-10 2024-09-25 Inventprise Inc MULTIVALENT PNEUMOCOCCAL GLYCOCONJUGATE VACCINES CONTAINING AN EMERGING 24F SEROTYPE
KR20230056727A (ko) 2020-08-26 2023-04-27 화이자 인코포레이티드 B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
GB202016165D0 (en) 2020-10-12 2020-11-25 Optivalent Ltd Vaccine
EP4232593A1 (en) 2020-10-22 2023-08-30 Pfizer Inc. Methods for purifying bacterial polysaccharides
MX2023004912A (es) 2020-10-27 2023-05-16 Pfizer Composiciones de escherichia coli y metodos de las mismas.
US20240000912A1 (en) 2020-11-04 2024-01-04 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20230405137A1 (en) 2020-11-10 2023-12-21 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
KR102610292B1 (ko) * 2021-02-10 2023-12-04 에스케이바이오사이언스(주) 스트랩토코커스 뉴모니애 다당류와 운반체 단백질의 접합체 제조 방법
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
JP2024517780A (ja) 2021-05-03 2024-04-23 ファイザー・インク 細菌およびベータコロナウイルス感染症に対するワクチン接種
MX2023013434A (es) 2021-05-28 2023-12-12 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
JP2024521847A (ja) 2021-05-28 2024-06-04 ファイザー・インク コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用
KR20240099160A (ko) 2021-09-09 2024-06-28 아피니백스, 인크. 다가 폐렴구균 백신
CN114106210A (zh) * 2021-11-09 2022-03-01 北京智飞绿竹生物制药有限公司 一种23价肺炎球菌多糖疫苗的生产工艺
IL314243A (en) 2022-01-13 2024-09-01 Pfizer Immunogenic preparations containing conjugates of capsular sugar antigen and their uses
GB2614916A (en) 2022-01-25 2023-07-26 Optivalent Ltd Intradermal vaccine complement
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
AU2023268745A1 (en) 2022-05-11 2024-11-07 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024062494A1 (en) 2022-09-19 2024-03-28 Biological E Limited Method for the purification of capsular polysaccharides
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
WO2024110839A2 (en) 2022-11-22 2024-05-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37741A (en) 1863-02-24 Improvement in bee-hives
US4097666A (en) 1976-04-29 1978-06-27 The Institute Of Paper Chemistry Solvent system for polysaccharides
CA1115210A (en) 1977-11-28 1981-12-29 Dennis J. Carlo Pneumococcal vaccine
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5097020A (en) 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4619828A (en) 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
CH660375A5 (it) 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5110908A (en) 1986-12-31 1992-05-05 Praxis Biologics, Inc. Haemophilus influenzae peptides and proteins
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
KR100188323B1 (ko) 1989-03-09 1999-06-01 이곤 이이 버어그 비타입성 헤모필루스 인플렌자에 대한 백신
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
WO1993013302A1 (de) 1991-12-23 1993-07-08 Michael Zoche Motor mit einer vorrichtung zur entölung
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
ES2231770T3 (es) 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
DE122009000058I1 (de) 1993-09-22 2009-12-31 Jackson H M Found Military Med Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
US5712118A (en) 1993-09-29 1998-01-27 Research Foundation Of State University Of New York Vaccine for branhamella catarrhalis
US5770213A (en) 1994-05-05 1998-06-23 American Cyanamid Company Purified nontypable haemophilus influenzae P5 protein as a vaccine for nontypable haemophilus influenzae infection
US5607846A (en) 1994-05-17 1997-03-04 Research Foundation Of State University Of New York Vaccine for moraxella catarrhalis
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5643725A (en) 1994-07-19 1997-07-01 American Cyanamid Company Sequence and analysis of LKP pilin structural genes and the LKP pili operon of nontypable haemophilus influenzae
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US6676948B2 (en) 1994-08-25 2004-01-13 Washington University Haemophilus adherence and penetration proteins
US6245337B1 (en) 1994-08-25 2001-06-12 Washington University Haemophilus adherence and penetration proteins
US5714354A (en) 1995-06-06 1998-02-03 American Home Products Corporation Alcohol-free pneumococcal polysaccharide purification process
US5695768A (en) * 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
DE69730814T2 (de) 1996-07-26 2005-09-29 Wyeth Holdings Corp. Das NucA Protein von Haemophilus influenzae und dessen kodierendes Gen
ATE497004T1 (de) 1996-12-20 2011-02-15 Univ Texas Moraxella catarrhalis antigene uspa1 und uspa2
WO1998033814A1 (en) 1997-01-31 1998-08-06 American Cyanamid Company THE 74 KILODALTON OUTER MEMBRANE PROTEIN FROM $i(MORAXELLA CATARRHALIS)
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
ES2611464T3 (es) * 1997-12-23 2017-05-09 Pfizer Ireland Pharmaceuticals Polisacárido capsular bacteriano para su uso como vacuna o para su unión a proteínas en vacunas de conjugados
KR100585408B1 (ko) * 1998-02-12 2006-06-01 와이어쓰 홀딩스 코포레이션 인터루킨-12로 제형된 폐렴구균 및 수막구균 백신
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2233725A1 (en) * 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
AU6060899A (en) 1998-09-24 2000-04-10 American Cyanamid Company Human complement c3-degrading polypeptide from (streptococcus pneumoniae)
ES2293735T3 (es) 1998-09-30 2008-03-16 Wyeth Holdings Corporation Holotoxina del colera mutante como coadyuvante.
EP1034792A1 (en) 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
EP1035137A1 (en) 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Method for the reductive amination of polysaccharides
BR0009163A (pt) 1999-03-19 2001-12-26 Smithkline Beecham Biolog Vacina
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
DE60044352D1 (de) 1999-06-25 2010-06-17 Wyeth Corp Herstellung der lipid-modifizierten form des peptidoglykan-assoziierten lipoproteins aus gram-negativen bakterien
GB0011108D0 (en) 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
GB0012079D0 (en) 2000-05-18 2000-07-12 Microscience Ltd Virulence gene and protein, and their use
OA12302A (en) * 2000-06-29 2003-10-24 Glaxosmithkline Biolog Sa Multivalent vaccine composition.
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0020952D0 (en) 2000-08-24 2000-10-11 Microscience Ltd Genes and proteins and their uses
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
DE60103561T2 (de) 2000-12-13 2004-09-30 Sca Hygiene Products Zeist B.V. Rückgewinnungsprozess für gebrauchtes periodat
BR0116756A (pt) 2000-12-28 2005-01-04 Wyeth Corp Proteìna protetora recombinante de streptococcus pneumoniae e uso da mesma
WO2002083855A2 (en) 2001-04-16 2002-10-24 Wyeth Holdings Corporation Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
ATE451386T1 (de) 2001-06-07 2009-12-15 Wyeth Corp Mutantenformen von cholera holotoxin als adjuvans
IL159209A0 (en) 2001-06-07 2004-06-01 Wyeth Corp Mutant forms of cholera holotoxin as an adjuvant
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
WO2003009869A1 (en) 2001-07-26 2003-02-06 Chiron Srl. Vaccines comprising aluminium adjuvants and histidine
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP1461353A4 (en) 2001-11-29 2006-05-03 Wyeth Corp OPEN READING FRAMES (ORF) OF BACTERIUM ALLOIOCOCCUS OTITIDIS ENCODING ANTIGENIC POLYPEPTIDES, IMUNOGENIC COMPOSITIONS, AND USES THEREOF
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
IL163988A0 (en) 2002-03-15 2005-12-18 Wyeth Corp Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
AU2002309259A1 (en) 2002-05-09 2003-11-11 Massimo Porro Improved polysaccharide and glycoconjugate vaccines_____________
US20040096461A1 (en) 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
EP1549135A4 (en) 2002-09-20 2006-01-11 Us Agriculture VACCINE AND ADJUVANT COMPOSITIONS
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
CA2522751A1 (en) 2003-04-16 2004-11-04 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
CN1241937C (zh) * 2003-07-04 2006-02-15 上海健益科技发展有限公司 多价肺炎球菌多糖结合疫苗
EP2366403B1 (en) 2003-08-06 2014-10-08 The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services Polysaccharide-protein conjugate vaccines
US7582459B2 (en) 2003-09-11 2009-09-01 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Process for producing a capsular polysaccharide for use in conjugate vaccines
FR2857364B1 (fr) 2003-12-08 2005-09-23 Aventis Pasteur Dosage des acides techoiques des bacteries gram+
EA012984B1 (ru) 2003-12-17 2010-02-26 Вайет Конъюгаты иммуногенных пептидных носителей и способы их получения
US20060022838A1 (en) 2004-07-27 2006-02-02 Fisher Richard A Speed limit indicia for traffic signals
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CA3165042A1 (en) * 2005-04-08 2006-10-19 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
JP5579387B2 (ja) 2005-12-22 2014-08-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 肺炎連鎖球菌莢膜多糖類コンジュゲートを含むワクチン
NZ574776A (en) 2006-09-29 2012-03-30 Japan Poliomyelitis Res Inst Proccess for producing poliovirus in culture using a dextran microcarrier for use in an inactivated poliovirus, diptheria, pertussis and tetanus vaccine
EP2687228B1 (en) 2007-06-26 2017-07-19 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
AU2008340949A1 (en) 2007-12-24 2009-07-02 Glaxosmithkline Biologicals S.A. Recombinant RSV antigens
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075201A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CA3170344C (en) 2014-01-21 2023-08-29 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2018225099B2 (en) * 2017-02-24 2024-08-22 Merck Sharp & Dohme Llc Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates

Also Published As

Publication number Publication date
EP2425851A1 (en) 2012-03-07
KR101730749B1 (ko) 2017-04-26
CA2986862C (en) 2022-09-27
AU2006235013A1 (en) 2006-10-19
CA2604363A1 (en) 2006-10-19
IL228035A0 (en) 2013-09-30
CL2017002206A1 (es) 2018-03-23
KR102017842B1 (ko) 2019-09-03
KR20130048262A (ko) 2013-05-09
KR20150061019A (ko) 2015-06-03
KR102611449B1 (ko) 2023-12-06
US9981035B2 (en) 2018-05-29
US8895024B2 (en) 2014-11-25
CN108404126B (zh) 2022-10-18
KR102564388B1 (ko) 2023-08-08
TW200719911A (en) 2007-06-01
ZA200709483B (en) 2009-03-25
BRPI0607025B1 (pt) 2019-11-12
US20140314805A1 (en) 2014-10-23
CA2986862A1 (en) 2006-10-19
CN113198013A (zh) 2021-08-03
CL2016000566A1 (es) 2016-10-28
EP4005595A1 (en) 2022-06-01
JP2009161567A (ja) 2009-07-23
KR101730750B1 (ko) 2017-04-26
KR20230118200A (ko) 2023-08-10
AU2006235013B2 (en) 2011-11-03
CA3165042A1 (en) 2006-10-19
BRPI0607025A2 (pt) 2009-07-28
KR20150061020A (ko) 2015-06-03
EP2425852A1 (en) 2012-03-07
IL267125A (en) 2019-08-29
KR20170086139A (ko) 2017-07-25
BRPI0607025B8 (pt) 2021-05-25
NZ562406A (en) 2009-09-25
US20180250390A1 (en) 2018-09-06
KR20220042483A (ko) 2022-04-05
DK1868645T3 (da) 2012-04-10
US10716848B2 (en) 2020-07-21
PT1868645E (pt) 2012-05-17
IL267125B (en) 2021-05-31
KR102220506B1 (ko) 2021-03-02
TWI386222B (zh) 2013-02-21
ATE548051T1 (de) 2012-03-15
EP2425855A1 (en) 2012-03-07
ES2382048T3 (es) 2012-06-04
CN102716480B (zh) 2023-03-21
KR20070118700A (ko) 2007-12-17
TW201438734A (zh) 2014-10-16
KR20190104241A (ko) 2019-09-06
EP3311836A1 (en) 2018-04-25
EP2425854A1 (en) 2012-03-07
MX2019008863A (es) 2019-09-13
JP2008535838A (ja) 2008-09-04
KR101298053B1 (ko) 2013-08-20
WO2006110381A1 (en) 2006-10-19
MY145150A (en) 2011-12-30
HK1213184A1 (zh) 2016-06-30
IL308456A (en) 2024-01-01
HRP20120278T1 (hr) 2012-04-30
PL1868645T3 (pl) 2012-07-31
US8808708B2 (en) 2014-08-19
US20090130137A1 (en) 2009-05-21
CN101180079A (zh) 2008-05-14
JP2013006881A (ja) 2013-01-10
CN113198012A (zh) 2021-08-03
HK1257962A1 (zh) 2019-11-01
EP1868645A1 (en) 2007-12-26
US10780160B2 (en) 2020-09-22
US20200179508A1 (en) 2020-06-11
KR20150061018A (ko) 2015-06-03
CN113198013B (zh) 2024-02-20
EP2425856A1 (en) 2012-03-07
CY1112777T1 (el) 2016-02-10
JP5730261B2 (ja) 2015-06-03
SI1868645T1 (sl) 2012-04-30
JP4472770B2 (ja) 2010-06-02
KR101730748B1 (ko) 2017-04-26
US9399060B2 (en) 2016-07-26
IL186367A0 (en) 2008-01-20
CN102716480A (zh) 2012-10-10
IL186367A (en) 2013-09-30
US20190388537A1 (en) 2019-12-26
EP2425853A1 (en) 2012-03-07
CN104815327A (zh) 2015-08-05
EP1868645B1 (en) 2012-03-07
JP5173920B2 (ja) 2013-04-03
US20160158345A1 (en) 2016-06-09
US11191830B2 (en) 2021-12-07
MX358148B (es) 2018-08-07
TWI511739B (zh) 2015-12-11
CA2878579A1 (en) 2006-10-19
CA2604363C (en) 2015-06-16
KR20210022768A (ko) 2021-03-03
RS52249B (en) 2012-10-31
AR107018A2 (es) 2018-03-14
TWI445545B (zh) 2014-07-21
KR20150061021A (ko) 2015-06-03
CA2878579C (en) 2018-01-23
CN101180079B (zh) 2012-07-18
ME01334B (me) 2013-12-20
US20210283247A1 (en) 2021-09-16
US20060228380A1 (en) 2006-10-12
KR101588939B1 (ko) 2016-01-26
CN113198012B (zh) 2024-09-17
US20120237542A1 (en) 2012-09-20
MX2007012336A (es) 2007-11-21
TW201212937A (en) 2012-04-01
AR053354A1 (es) 2007-05-02
CN108404126A (zh) 2018-08-17
IL282638A (en) 2021-06-30
SA06270323B1 (ar) 2010-10-05
KR102378962B1 (ko) 2022-03-28

Similar Documents

Publication Publication Date Title
HK1257962A1 (zh) 多價肺炎球菌多糖-蛋白質綴合物組合物
ZA200904619B (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
ZA200904331B (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
HRP20190037T1 (hr) Cjepivo na bazi konjugata pneumokoknih polisaharida
PL1968630T3 (pl) Multiwalentne immunogenne kompozycje PCV2
AP2436A (en) Immunogenic composition
IL198466A0 (en) Immunization protocol against the 4 dengue serotypes
EP1976974A4 (en) Pneumococcal SEROTYPES
GB0526038D0 (en) Immunogenic composition
GB0513069D0 (en) Immunogenic composition
EP1963522A4 (en) MULTIVALENT MENINGOCOCCAL DERIVATIVE POLYSACCHARIDE-PROTEIN CONJUGATES AND VACCINE
ZA200805347B (en) Pneumococcal polysaccharide conjugate vaccine
GB0513071D0 (en) Immunogenic composition
GB0515556D0 (en) Immunogenic composition
GB0524204D0 (en) Immunogenic composition
GB0526040D0 (en) Immunogenic composition
GB0503143D0 (en) Immunogenic composition
GB0526041D0 (en) Immunogenic composition